Neurol. praxi. 2014;15(3):136-140

Link atrophy and disability in multiple sclerosis

MUDr. Jiří Pi»ha
MS Centrum Teplice Neurologické oddělení KZ a.s. &ndash, Nemocnice Teplice o. z.

Brain and spinal cord atrophy in multiple sclerosis occurs due to neurodegeneration either demyelinated axons or their direct damage. The development of unconventional techniques of magnetic resonance imaging allows accurate assessment of global or regional atrophy that correlates with disability. Some of already registered drugs and others that are in the stage of clinical testing show a neuroprotective effect, affecting disability and therefore quality of life.

Keywords: multiple sclerosis, atrophy, pseudoatrophy, disability, neuroprotection

Published: June 9, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pi»ha J. Link atrophy and disability in multiple sclerosis. Neurol. praxi. 2014;15(3):136-140.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Barkhof F, Hulst HE, Drulovic J, Uitdehaag BM, Matsuda K, Landin R; MN166-001 Investigators. Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant? Neurology. 2010; 74(13): 1033-1040. Go to original source... Go to PubMed...
    2. Calabrese M, Rinaldi F, Grossi P, Mattisi I, Bernardi V, Favaretto A, Perini P, Gallo P. Basal ganglia and frontal/parietal cortical atrophy is associated with fatigue in relapsing-remitting multiple sclerosis. Mult Scler. 2010; 16(10): 1220-1228. Go to original source... Go to PubMed...
    3. Comi G, Jeffery D, Kappos L, Montalban X, Boyko A, Rocca MA, Filippi M; ALLEGRO Study Group. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med. 2012; 366(11): 1000-1009. Go to original source... Go to PubMed...
    4. Craner MJ, Newcombe J, Black JA, Hartle C, Cuzner ML, Waxman SG. Molecular changes in neurons in multiple sclerosis: altered axonal expression of Nav1.2 and Nav1.6 sodium channels and Na+/Ca2+ exchanger. Proc Natl Acad Sci U S A 2004; 101: 8168-8173. Go to original source... Go to PubMed...
    5. De Stefano N, Matthews PM, Filippi M, Agosta F, De Luca M, Bartolozzi ML, Guidi L, Ghezzi A, Montanari E, Cifelli A, Federico A, Smith SM. Evidence of early cortical atrophy in MS: relevance to white matter changes and disability. Neurology 2003; 60: 1157-1162. Go to original source... Go to PubMed...
    6. Henry RG, Shieh M, Okuda DT, Evangelista A, Gorno-Tempini ML, Pelletier D. Regional grey matter atrophy in clinically isolated syndromes at presentation. J Neurol Neurosurg Psychiatry. 2008; 79(11): 1236-1244. Go to original source... Go to PubMed...
    7. Chen M, Carass A, Oh J, Nair G, Pham DL, Reich DS, Prince JL. Automatic magnetic resonance spinal cord segmentation with topology constraints for variable fields of view. Neuroimage. 2013; 83: 1051-1062. Go to original source... Go to PubMed...
    8. Jacobsen C, Hagemeier J, Myhr KM, Nyland H, Lode K, Bergsland N, Ramasamy DP, Dalaker TO, Larsen JP, Farbu E, Zivadinov R. Brain atrophy and disability progression in multiple sclerosis patients: a 10-year follow-up study. J Neurol Neurosurg Psychiatry. 2014; 85: 119-120. Go to original source... Go to PubMed...
    9. Jasperse B, Vrenken H, Sanz-Atigita E, se Groot V, Smith SM, Polman CH, Barkhof F, Regional brain atrophy developlment is related to specific aspects of clinical dysfuncion in multiple sclerosis. Neuroimage 2007; 38: 529-537. Go to original source... Go to PubMed...
    10. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P; FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010; 362(5): 387-401. Go to original source... Go to PubMed...
    11. Lassmann H. Mechanisms of inflammation induced tissue injury in multiple sclerosis. J Neurol Sci; 2008, 274: 45-47. Go to original source... Go to PubMed...
    12. Lucchinetti CF, Popescu BF, Bunyan RF, Moll NM, Roemer SF, Lassmann H, Brück W, Parisi JE, Scheithauer BW, Giannini C, Weigand SD, Mandrekar J. Ransohoff RM. Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med 2011; 365: 2188-2197. Go to original source... Go to PubMed...
    13. Miller DH, Soon D, Fernando KT, MacManus DG, Barker GJ, Yousry TA, Fisher E, O'Connor PW, Phillips JT, Polman CH, Kappos L, Hutchinson M, Havrdova E, Lublin FD, Giovannoni G, Wajgt A, Rudick R, Lynn F, Panzara MA, Sandrock AW; AFFIRM Investigators. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology. 2007; 68(17): 1390-1401. Go to original source... Go to PubMed...
    14. Mistry N, Abdel-Fahim R, Mougin O, Tench C, Gowland P, Evangelou N. Cortical lesion load correlates with diffuse injury of multiple sclerosis normal appearing white matter. Mult Scler. 2014; 20(2): 227-233. Go to original source... Go to PubMed...
    15. Paling D, Golay X, Wheeler-Kingshott C, Kapoor R, Miller D. Energy failure in multiple sclerosis and its investigation using MR techniques. J Neurol 2011; 258: 2113-2127. Go to original source... Go to PubMed...
    16. Popescu V, Agosta F, Hulst HE, Sluimer IC, Knol DL, Sormani MP, Enzinger C, Ropele S, Alonso J, Sastre-Garriga J, Rovira A, Montalban X, Bodini B, Ciccarelli O, Khaleeli Z, Chard DT, Matthews L, Palace J, Giorgio A, De Stefano N, Eisele P, Gass A, Polman CH, Uitdehaag BM, Messina MJ, Comi G, Filippi M, Barkhof F, Vrenken H; MAGNIMS Study Group. Brain atrophy and lesion load predict long term disability in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2013; 84(10): 1082-1091. Go to original source... Go to PubMed...
    17. Roosendaal SD, Bendfeldt K, Vrenken H, Polman CH, Borgwardt S, Radue EW, Kappos L, Pelletier D, Hauser SL, Matthews PM, Barkhof F, Geurts JJ. Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability. Mult Scler. 2011; 17(9): 1098-1106. Go to original source... Go to PubMed...
    18. Rovaris M, Comi G, Rocca MA, Wolinsky JS, Filippi M. European/Canadian Glatiramer Acetate Study Group. Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications. Brain 2001; 124(9): 1803-1812. Go to original source... Go to PubMed...
    19. Rudick RA, Fisher E, Lee JC, Simon J, Jacobs L. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Neurology 1999; 53: 1698-1704. Go to original source... Go to PubMed...
    20. Sormani MP, Arnold DL, De Stefano N. Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. Ann Neurol. 2014; 75(1): 43-49. Go to original source... Go to PubMed...
    21. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 1998; 338(5): 278-285. Go to original source... Go to PubMed...
    22. Valsasina P, Rocca MA, Horsfield MA, Absinta M, Messina R, Caputo D, Comi G, Filippi M. Regional cervical cord atrophy and disability in multiple sclerosis: a voxel-based analysis. Radiology. 2013; 266(3): 853-861. Go to original source... Go to PubMed...
    23. Yaldizli O, Penner IK, Frontzek K, Naegelin Y, Amann M, Papadopoulou A, Sprenger T, Kuhle J, Calabrese P, Radü EW, Kappos L, Gass A.The relationship between total and regional corpus callosum atrophy, cognitive impairment and fatigue in multiple sclerosis patients. Mult Scler. 2014; 20(3): 356-364. Go to original source... Go to PubMed...
    24. Zivadinov R, Havrdová E, Bergsland N, Tyblova M, Hagemeier J, Seidl Z, Dwyer MG, Vaneckova M, Krasensky J, Carl E, Kalincik T, Horáková D. Thalamic atrophy is associated with development of clinically definite multiple sclerosis. Radiology. 2013; 268(3): 831-841. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.